Literature DB >> 29725441

Forkhead box N1 inhibits the progression of non-small cell lung cancer and serves as a tumor suppressor.

Xiaojian Ji1, Yan Ji2, Wenqing Wang1, Xinmei Xu1.   

Abstract

Forkhead box N1 (FOXN1) belongs to the FOX family of transcription factors, which comprises a diverse group of winged-helix proteins. FOXN1 is a ubiquitously expressed member that has been implicated in the embryo development, metabolism, aging and cancer. However, little is known regarding the role of FOXN1 in non-small cell lung cancer (NSCLC). The aim of the study was to investigate the function of FOXN1 in NSCLC and examine the relevant mechanism. In the present study, using reverse transcription-quantitative polymerase chain reaction, western blotting, transwell assay, MTT assay, luciferase report assy, it was identified that knockdown of FOXN1 increased the proliferation of A549 and H1299 cells, while overexpression of FOXN1 evidently suppressed the cell growth. A Transwell assay was used to determine the relative cell invasion ability, and it was observed that the invading cells were markedly decreased in the FOXN1 overexpression groups; by contrast, reduced expression of FOXN1 demonstrated the potential to promote cell invasion. Furthermore, lower expression of FOXN1 was observed in NSCLC tissues and cell lines as compared with the adjacent non-tumor tissues or human bronchial epithelial cells, respectively. A higher level of FOXN1 was associated with a better prognosis of NSCLC patients. Quantitative chromatin immunoprecipitation analysis and luciferase reporter gene assays revealed that enhancer of zeste homolog 2 (EZH2) and β-catenin were two target genes of FOXN1. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis indicated that FOXN1 suppressed the expression levels of these target genes at the transcriptional level. In conclusion, the present study demonstrated that FOXN1 served major roles in NSCLC proliferation and invasion by directly repressing EZH2 and β-catenin, which suggested that FOXN1 may function as a tumor suppressor in NSCLC.

Entities:  

Keywords:  enhancer of zeste homolog 2; forkhead box N1; invasion; non-small cell lung cancer; proliferation; β-catenin

Year:  2018        PMID: 29725441      PMCID: PMC5920490          DOI: 10.3892/ol.2018.8210

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Validation of the proposed International Association for the Study of Lung Cancer non-small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry.

Authors:  Jason A Zell; S-H Ignatius Ou; Argyrios Ziogas; Hoda Anton-Culver
Journal:  J Thorac Oncol       Date:  2007-12       Impact factor: 15.609

3.  Update in lung cancer: prologue to a modern review series.

Authors:  Nico van Zandwijk; Kwun M Fong
Journal:  Respirology       Date:  2015-02       Impact factor: 6.424

4.  New therapeutic target for non-small-cell lung cancer.

Authors:  Sharan Prakash Sharma
Journal:  Lancet Oncol       Date:  2014-10-07       Impact factor: 41.316

5.  EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.

Authors:  Jian Geng; Xiao Li; Zhanmei Zhou; Chin-Lee Wu; Meng Dai; Xiaoyan Bai
Journal:  Cancer Lett       Date:  2015-01-26       Impact factor: 8.679

6.  FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells.

Authors:  Tian Yang; Hong Li; Asmitananda Thakur; Tianjun Chen; Jing Xue; Dan Li; Mingwei Chen
Journal:  Tumour Biol       Date:  2015-05-21

7.  High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer.

Authors:  Jian Feng; Xuesong Zhang; Huijun Zhu; Xudong Wang; Songshi Ni; Jianfei Huang
Journal:  Am J Clin Pathol       Date:  2012-08       Impact factor: 2.493

Review 8.  WNT and beta-catenin signalling: diseases and therapies.

Authors:  Randall T Moon; Aimee D Kohn; Giancarlo V De Ferrari; Ajamete Kaykas
Journal:  Nat Rev Genet       Date:  2004-09       Impact factor: 53.242

9.  EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer.

Authors:  Chunhua Xu; Zhibo Hou; Ping Zhan; Wei Zhao; Cunjie Chang; Jue Zou; Huidi Hu; Yuanqin Zhang; Xin Yao; Like Yu; Jun Yan
Journal:  Med Oncol       Date:  2013-10-17       Impact factor: 3.064

10.  MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells.

Authors:  Ziqiang Zhu; Jinshan Tang; Jianqiang Wang; Gang Duan; Lei Zhou; Xiaoqing Zhou
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

View more
  3 in total

1.  Coexpression of FOXK1 and vimentin promotes EMT, migration, and invasion in gastric cancer cells.

Authors:  Hui Zhang; Xiaosheng Wu; Yizhi Xiao; Liqing Wu; Ying Peng; Weimei Tang; Guangnan Liu; Yong Sun; Jing Wang; Huiqiong Zhu; Mengwei Liu; Wenjing Zhang; Weiyu Dai; Ping Jiang; Aimin Li; Guoxin Li; Li Xiang; Side Liu; Jide Wang
Journal:  J Mol Med (Berl)       Date:  2018-11-27       Impact factor: 4.599

2.  Overexpression of miR-518b in non-small cell lung cancer serves as a biomarker and facilitates tumor cell proliferation, migration and invasion.

Authors:  Xinfang Zhang; Ying Hu; Cuixue Gong; Chunjie Zhang
Journal:  Oncol Lett       Date:  2020-05-22       Impact factor: 2.967

3.  Chemical evolution for taming the 'pathogenic kinase' PAK1.

Authors:  Hiroshi Maruta; Atsushi Kittaka
Journal:  Drug Discov Today       Date:  2020-04-26       Impact factor: 7.851

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.